Shanghai Kehua Bio-Engineering Co Ltd (002022) - Net Assets

Latest as of March 2026: CN¥3.05 Billion CNY ≈ $446.40 Million USD

Based on the latest financial reports, Shanghai Kehua Bio-Engineering Co Ltd (002022) has net assets worth CN¥3.05 Billion CNY (≈ $446.40 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.55 Billion ≈ $665.33 Million USD) and total liabilities (CN¥1.50 Billion ≈ $218.93 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Shanghai Kehua Bio-Engineering Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥3.05 Billion
% of Total Assets	67.1%
Annual Growth Rate	14.14%
5-Year Change	-39.4%
10-Year Change	63.6%
Growth Volatility	30.14

Shanghai Kehua Bio-Engineering Co Ltd - Net Assets Trend (2001–2025)

This chart illustrates how Shanghai Kehua Bio-Engineering Co Ltd's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Shanghai Kehua Bio-Engineering Co Ltd to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Shanghai Kehua Bio-Engineering Co Ltd (2001–2025)

The table below shows the annual net assets of Shanghai Kehua Bio-Engineering Co Ltd from 2001 to 2025. For live valuation and market cap data, see 002022 company net worth.

Year	Net Assets	Change
2025-12-31	CN¥3.11 Billion ≈ $455.03 Million	-21.92%
2024-12-31	CN¥3.98 Billion ≈ $582.75 Million	-20.10%
2023-12-31	CN¥4.98 Billion ≈ $729.35 Million	-14.83%
2022-12-31	CN¥5.85 Billion ≈ $856.33 Million	+14.05%
2021-12-31	CN¥5.13 Billion ≈ $750.87 Million	+31.60%
2020-12-31	CN¥3.90 Billion ≈ $570.55 Million	+44.92%
2019-12-31	CN¥2.69 Billion ≈ $393.70 Million	+10.72%
2018-12-31	CN¥2.43 Billion ≈ $355.59 Million	+16.88%
2017-12-31	CN¥2.08 Billion ≈ $304.24 Million	+9.39%
2016-12-31	CN¥1.90 Billion ≈ $278.14 Million	+10.15%
2015-12-31	CN¥1.73 Billion ≈ $252.51 Million	+36.13%
2014-12-31	CN¥1.27 Billion ≈ $185.50 Million	+4.93%
2013-12-31	CN¥1.21 Billion ≈ $176.79 Million	+11.20%
2012-12-31	CN¥1.09 Billion ≈ $158.98 Million	+5.90%
2011-12-31	CN¥1.03 Billion ≈ $150.12 Million	+10.15%
2010-12-31	CN¥931.34 Million ≈ $136.28 Million	+17.47%
2009-12-31	CN¥792.82 Million ≈ $116.01 Million	+23.16%
2008-12-31	CN¥643.75 Million ≈ $94.20 Million	+32.33%
2007-12-31	CN¥486.48 Million ≈ $71.19 Million	+22.23%
2006-12-31	CN¥398.02 Million ≈ $58.24 Million	+4.55%
2005-12-31	CN¥380.71 Million ≈ $55.71 Million	-0.29%
2004-12-31	CN¥381.82 Million ≈ $55.87 Million	+140.25%
2003-12-31	CN¥158.92 Million ≈ $23.26 Million	+8.70%
2002-12-31	CN¥146.21 Million ≈ $21.39 Million	+12.50%
2001-12-31	CN¥129.97 Million ≈ $19.02 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Shanghai Kehua Bio-Engineering Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 12568.3% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥1.71 Billion	64.84%
Other Components	CN¥927.57 Million	35.16%
Total Equity	CN¥2.64 Billion	100.00%

Shanghai Kehua Bio-Engineering Co Ltd Competitors by Market Cap

The table below lists competitors of Shanghai Kehua Bio-Engineering Co Ltd ranked by their market capitalization.

Company	Market Cap
Gladstone Investment Corporation 8.00% Notes due 2028 NASDAQ:GAINL	$358.34 Million
Hanjia Design Croup Co Ltd Class A SHE:300746	$358.40 Million
Shenyang Chemical Industry Co Ltd SHE:000698	$358.56 Million
Clinuvel Pharmaceuticals Ltd AU:CUV	$358.59 Million
Greenyard NV BR:GREEN	$358.22 Million
Primis Financial Corp NASDAQ:FRST	$358.20 Million
Columbus McKinnon Corporation NASDAQ:CMCO	$358.09 Million
Egis Technology TWO:6462	$357.92 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shanghai Kehua Bio-Engineering Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 3,349,826,403 to 2,637,914,841, a change of -711,911,562 (-21.3%).
Net loss of 732,140,994 reduced equity.
Dividend payments of 15,445,516 reduced retained earnings.
Other factors increased equity by 35,674,948.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥-732.14 Million	-27.75%
Dividends Paid	CN¥15.45 Million	-0.59%
Other Changes	CN¥35.67 Million	+1.35%
Total Change	CN¥-	-21.25%

Book Value vs Market Value Analysis

This analysis compares Shanghai Kehua Bio-Engineering Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.93x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 29.88x to 0.93x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2001-12-31	CN¥0.16	CN¥4.76	x
2002-12-31	CN¥0.18	CN¥4.76	x
2003-12-31	CN¥0.31	CN¥4.76	x
2004-12-31	CN¥1.04	CN¥4.76	x
2005-12-31	CN¥1.13	CN¥4.76	x
2006-12-31	CN¥1.14	CN¥4.76	x
2007-12-31	CN¥0.92	CN¥4.76	x
2008-12-31	CN¥1.23	CN¥4.76	x
2009-12-31	CN¥1.53	CN¥4.76	x
2010-12-31	CN¥1.84	CN¥4.76	x
2011-12-31	CN¥1.99	CN¥4.76	x
2012-12-31	CN¥2.07	CN¥4.76	x
2013-12-31	CN¥2.30	CN¥4.76	x
2014-12-31	CN¥2.54	CN¥4.76	x
2015-12-31	CN¥3.31	CN¥4.76	x
2016-12-31	CN¥3.60	CN¥4.76	x
2017-12-31	CN¥3.89	CN¥4.76	x
2018-12-31	CN¥4.24	CN¥4.76	x
2019-12-31	CN¥4.59	CN¥4.76	x
2020-12-31	CN¥6.13	CN¥4.76	x
2021-12-31	CN¥7.28	CN¥4.76	x
2022-12-31	CN¥9.03	CN¥4.76	x
2023-12-31	CN¥7.83	CN¥4.76	x
2024-12-31	CN¥6.63	CN¥4.76	x
2025-12-31	CN¥5.13	CN¥4.76	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shanghai Kehua Bio-Engineering Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -27.75%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -44.58%
• Asset Turnover: 0.35x
• Equity Multiplier: 1.76x
Recent ROE (-27.75%) is below the historical average (16.70%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2001	31.96%	19.86%	0.79x	2.04x	CN¥17.99 Million
2002	35.32%	18.44%	0.77x	2.50x	CN¥22.86 Million
2003	35.67%	16.46%	0.90x	2.41x	CN¥25.70 Million
2004	12.84%	17.92%	0.54x	1.33x	CN¥9.48 Million
2005	16.56%	18.77%	0.66x	1.34x	CN¥22.35 Million
2006	19.85%	21.99%	0.70x	1.29x	CN¥37.01 Million
2007	25.70%	29.57%	0.65x	1.33x	CN¥72.08 Million
2008	27.02%	34.09%	0.66x	1.20x	CN¥104.61 Million
2009	27.04%	32.90%	0.67x	1.23x	CN¥128.78 Million
2010	25.04%	28.83%	0.72x	1.21x	CN¥135.30 Million
2011	23.17%	25.95%	0.73x	1.23x	CN¥128.88 Million
2012	23.49%	23.66%	0.79x	1.26x	CN¥137.72 Million
2013	25.47%	25.87%	0.81x	1.21x	CN¥175.11 Million
2014	23.23%	23.97%	0.85x	1.14x	CN¥166.30 Million
2015	12.58%	18.22%	0.56x	1.24x	CN¥43.22 Million
2016	12.60%	16.64%	0.60x	1.26x	CN¥47.92 Million
2017	10.90%	13.66%	0.59x	1.36x	CN¥18.01 Million
2018	9.54%	10.44%	0.57x	1.61x	CN¥-9.94 Million
2019	8.59%	8.39%	0.65x	1.57x	CN¥-33.24 Million
2020	21.50%	16.25%	0.70x	1.90x	CN¥361.26 Million
2021	21.96%	17.52%	0.70x	1.80x	CN¥463.17 Million
2022	20.18%	13.94%	0.79x	1.83x	CN¥490.07 Million
2023	-5.81%	-9.64%	0.36x	1.69x	CN¥-636.98 Million
2024	-19.12%	-36.41%	0.34x	1.56x	CN¥-975.58 Million
2025	-27.75%	-44.58%	0.35x	1.76x	CN¥-995.93 Million

Industry Comparison

This section compares Shanghai Kehua Bio-Engineering Co Ltd's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $2,759,401,880
Average return on equity (ROE) among peers: 15.85%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Shanghai Kehua Bio-Engineering Co Ltd (002022)	CN¥3.05 Billion	31.96%	0.49x	$358.26 Million
Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223)	$8.43 Billion	17.59%	0.42x	$3.83 Billion
Double Medical Technology Inc (002901)	$580.13 Million	37.81%	0.24x	$2.55 Billion
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)	$2.85 Billion	49.59%	0.20x	$483.16 Million
Lepu Medical Tech Beijing (300003)	$8.00 Billion	21.55%	0.99x	$3.24 Billion
INKON Life Technology Co Ltd (300143)	$1.37 Billion	-51.44%	0.43x	$752.32 Million
Edan Instruments Inc (300206)	$1.73 Billion	13.36%	0.18x	$1.06 Billion
Guangdong Biolight Meditech Co Ltd (300246)	$427.94 Million	7.90%	0.21x	$604.04 Million
Beijing Leadman Biochemistry Co Ltd (300289)	$1.43 Billion	5.13%	0.23x	$451.37 Million
Sinocare Inc (300298)	$17.42 Million	41.15%	0.68x	$1.15 Billion

About Shanghai Kehua Bio-Engineering Co Ltd

SHE:002022 China Medical Devices

Market Cap

$358.26 Million

CN¥2.45 Billion CNY

Market Cap Rank

#13939 Global

#4148 in China

Share Price

CN¥4.76

Change (1 day)

-3.05%

52-Week Range

CN¥4.76 - CN¥8.06

All Time High

CN¥29.42